US MedTech: NY Valves 2026: Day Two Brings More to the Data Fest

Research evidence excerpt

US MedTech: NY Valves 2026: Day Two Brings More to the Data Fest

Flash |

25 Jun 2026 16:28:46 ET │ 11 pages

US MedTech

NY Valves 2026: Day Two Brings More to the Data Fest

CITI’S TAKE

Day two of NY Valves 2026 focused on expanding structural heart

opportunities. Mitral valve data continues to build clinical support for

transcatheter technology, where discussions regarding Edwards

Lifesciences’s PASCAL and Abbott’s MitraClip were constructive, with

Real-World Evaluation of MitraClip versus PASCAL for M-TEER Joanne WuenschAC

demonstrating that both devices had “similar procedural safety and +1-212-816-9606

efficacy” and reduction to MR ≤1+ at 30 days. Elsewhere, the discussion joanne.wuensch@citi.com

included the opportunity for valve-in-valve surgeries, estimating the U.S.

Anthony Occhiogrosso

market to reach ~42k procedures by 2035 from ~13k today. Further,

+1-212-816-7579

patient lifetime management discussions emphasized that while current anthony.occhiogrosso@citi.com

data does not suggest avoiding Low Risk patients, it does encourage

thorough evaluation by the heart team (a sentiment that echoes the TAVR Jane-Marie Lai

NCD language, link). Elsewhere, panelists named Medtronic’s Evolut as an +1-212-816-3628

“easy and appealing option” for valve-in-valve procedures as part of janemarie.lai@citi.com

patients’ lifetime management. We rate ABT, EW (Top Pick) and MDT Buy. Nikhil Guddeti

+1-212-816-2606

Clinical data also seems to paint PASCAL favorably. Specifically, One-Year nikhiltej.guddeti@citi.com

Outcomes from PASCAL M-TEER demonstrated: 1) “significant” mitral regurgitation

reduction; 2) high survival and low event rates; and 3) “clinically meaningful and

sustained improvements” in functional status and quality of life. These findings